<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<TITLE>$titleTag</TITLE>
<STYLE type="text/css">
   subtoolbar {border-top-width: 0px; border-top-style: none;}


   
 </STYLE>	
</head>
<body>
	
	<table width="940" height="496" border="0" align="center" cellpadding="0" cellspacing="0">
		<tr>
			<td height="489" align="right" valign="top"><SPAN><BR><INPUT type="BUTTON" name="BUTTON" value="< BACK" onclick="javascript: history.go(-1)" /></SPAN><BR>
			<table width="100%">
				<tr valign="top" align="left" style="color:#0066FF">
					<th width="33%">j50000007</th>
					<th width="33%">i40026185</th>
					<th width="33%"><A HREF='http://phoenix.jstor.org/Phoenix/toc/secure/issue.html?workType=mod&journalId=10.2307/j50000007&issueId=10.2307_i40026185' target='_blank'>PHX Link</A></th>
				</tr>
			</table>
			<P align='left' style='color:#993300'><B><u>10.2307/40599275</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Pelvic pain is a major component of the morbidity associated with urinary tract infection (UTI), yet the molecular mechanisms underlying UTI-induced pain remain unknown. UTI pain mechanisms probably contrast with the clinical condition of asymptomatic bacteriuria (ASB), characterized by significant bacterial loads without lack symptoms.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Pelvic pain is a major component of the morbidity associated with urinary tract infection (UTI), yet the molecular mechanisms underlying UTI-induced pain remain unknown. UTI pain mechanisms probably contrast with the clinical condition of asymptomatic bacteriuria (ASB), characterized by significant bacterial loads without lack symptoms.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. A murine UTI model was used to compare pelvic pain behavior elicited by infection with uropathogenic Escherichia coli strain NU14 and ASB strain 83972.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. NU14-infected mice exhibited pelvic pain, whereas mice infected with 83972 did not exhibit pain, similar to patients infected with 83972. NU14-induced pain was not dependent on mast cells, not correlated with bacterial colonization or urinary neutrophils. UTI pain was not influenced by expression of type 1 pili, the bacterial adhesive appendages that induce urothelial apoptosis. However, purified NU14 lipopolysaccharide (LPS) induced Toll-like receptor 4 (TLR4)-dependent pain, whereas 83972 LPS induced no pain. Indeed, 83972 LPS attenuated the pain of NU14 infection, suggesting therapeutic potential.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. These data suggest a novel mechanism of infection-associated pain that is dependent on TLR4 yet independent of inflammation. Clinically, these findings also provide the rational for probiotic therapies that would minimize the symptoms of infection without reliance on empirical therapies that contribute to antimicrobial resistance.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599272</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. A quadrivalent meningococcal conjugate vaccine (MCV4) was licensed in the United States in 2005; no serogroup vaccine is available. Neisseria meningitidis changes its capsular phenotype through capsular switching, which has implications for vaccines that do not protect against all serogroups.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. A quadrivalent meningococcal conjugate vaccine (MCV4) was licensed in the United States in 2005; no serogroup vaccine is available. Neisseria meningitidis changes its capsular phenotype through capsular switching, which has implications for vaccines that do not protect against all serogroups.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Meningococcal isolates from 10 Active Bacterial Core surveillance sites from 2000 through 2005 were analyzed to identify changes occurring after MCV4 licensure. Isolates were characterized by multilocus sequence typing (MLST) and outer membrane protein gene sequencing. Isolates expressing capsular polysaccharide different from that associated with the MLST lineage were considered to demonstrate capsular switching.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Among 1160 isolates, the most common genetic lineages were the sequence type (ST)-23, ST-32, ST-11, and ST-41/44 clonal complexes. Of serogroup and Y isolates, 8 (1.5%) and 3 (0.9%), respectively, demonstrated capsular switching, compared with 36 (12.9%) for serogroup (P<.001); most serogroup switches were from virulent serogroup and/or serogroup Y lineages.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions.A limited number of genetic lineages caused the majority of invasive meningococcal infections.A substantial proportion of isolates had evidence of capsular switching. The high prevalence of capsular switching requires surveillance to detect changes in the meningococcal population structure that may affect the effectiveness of meningococcal vaccines.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599273</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Ethambutol is used for the treatment of tuberculosis in cases where there is isoniazid resistance. We examined the emergence of drug resistance to ethambutol monotherapy in pharmacokinetic-pharmacodynamic studies of a hollow-fiber system.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Ethambutol is used for the treatment of tuberculosis in cases where there is isoniazid resistance. We examined the emergence of drug resistance to ethambutol monotherapy in pharmacokinetic-pharmacodynamic studies of a hollow-fiber system.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Dose-effect and dose-scheduling studies were performed with ethambutol and log-phase growth Mycobacterium tuberculosis to identify exposures and schedules linked to optimal kill and resistance suppression.In one study after 7 days of daily ethambutol, 300 mg isoniazid per day was administered to each system to determine its early bactericidal activity.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Efflux-pump blockage reduced the mutation frequency to ethambutol 64-fold. In dose-effect studies, ethambutol had a maximal early bactericidal activity of 0.22 log 10 colony-forming units/mL/day, as is encountered in patients. By day 7, resistance to both ethambutol and isoniazid had increased. Previous exposure to ethambutol halted isoniazid early bactericidal activity. Daily therapy, as opposed to more intermittent therapy, was associated with the least proportion of efflux-pump-driven resistance, consistent with a time-driven effect. Microbial kill was best explained by the ratio of area under the concentration-time curve to minimum inhibitory concentration (r² = 0.90).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. The induction of an efflux pump that reduces the effect of multiple drugs provides an alternative pathway to sequential acquisition of mutations in the development of multiple drug resistance.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599264</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Worldwide, ~90% of all human immunodeficiency virus (HIV) transmissions occur mucosally; almost all involve R5 strains. Risks of sexual HIV acquisition are highest for rectal, then vaginal, and finally oral exposures.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Worldwide, ~90% of all human immunodeficiency virus (HIV) transmissions occur mucosally; almost all involve R5 strains. Risks of sexual HIV acquisition are highest for rectal, then vaginal, and finally oral exposures.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Mucosal lacerations may affect the rank order of susceptibility to HIV but cannot be assessed in humans. We measured relative virus transmissibility across intact mucosae in macaques using a single stock of SHIV-1157ipd3N4, a simian-human immunodeficiency virus encoding a primary R5 HIV clade C env (SHIV-C).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. The penetrability of rhesus macaque mucosae differed significantly, with rectal challenge requiring the least virus, followed by vaginal and then oral routes (P = .031, oral vs vaginal; P< .001 rectal vs vaginal). These findings imply that intrinsic mucosal properties are responsible for the differential mucosal permeability. The latter paralleled the rank order reported for humans, with relative risk estimates within the range of epidemiological human studies. To test whether inflammation facilitates virus transmissionas predicted from human studieswe established a macaque model of localized buccal inflammation. Systemic infection occurred across inflamed but not normal buccal mucosa.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. Our primate data recapitulate virus transmission risks observed in humans, thus establishing R5 SHIV-1157ipd3N4 in macaques as a robust model system to study cofactors involved in human mucosal HIV transmission and its prevention.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599270</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Mutants of the a determinant of hepatitis surface antigen (HBsAg) can escape neutralization by vaccine-induced antibodies and prevail in an immunized population.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Mutants of the a determinant of hepatitis surface antigen (HBsAg) can escape neutralization by vaccine-induced antibodies and prevail in an immunized population.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. We evaluated the a mutants in a pédiatrie population surveyed in 2004 and compared these findings with the data of previous surveys.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. There were 38 children and 74 adolescents who were HBsAg positive, and serum hepatitis virus (HBV) DNA was obtained and tested from 31 and 34 of them, respectively. The a mutants were found in 7 (22.6%) of 31 HBV DNA-positive children and in 7 (0.10%) of 7234 children, the entire population that was surveyed in 2004. After the beginning of universal immunization, the very low prevalence of mutants has remained unchanged for 20 years. More a mutants were found in immunized than in nonimmunized HBV DNA-positive children aged 1-4 years old (31% vs 4%, P = .016) but not in those children aged 5-12 years old. Approximately 68% of immunized, mutant-infected children had carrier mothers. More a mutants emerged in children immunized with plasma-derived vaccines than in those immunized with recombinant vaccines (14 of 5166 vs 3 of 4970, respectively; P = .04). HBV DNA levels were significantly lower in hepatitis e antigen-positive sera containing the G145R mutant than were levels in sera containing wild-type virus. HBsAg-negative sera containing a mutants had very low HBV DNA levels.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. Less infectivity of G145R, recombinant vaccine use, and mutant loss with older age seem to decrease the a mutant prevalence in an immunized population over time.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599260</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. South African guidelines recommend protease-inhibitor-based antiretroviral therapy (ART) with lopinavir-ritonavir for human immunodeficiency virus (HlV)-infected children <36 months of age. We investigated factors associated with viral suppression and mortality among young children initiating ART.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. South African guidelines recommend protease-inhibitor-based antiretroviral therapy (ART) with lopinavir-ritonavir for human immunodeficiency virus (HlV)-infected children <36 months of age. We investigated factors associated with viral suppression and mortality among young children initiating ART.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Treatment-naive, ART-eligible, HIV-infected children (aged 6-104 weeks) were enrolled in an ART strategies trial in South Africa and initiated protease-inhibitor-based ART. Mortality and the probability of viral suppression (defined as HIV RNA load of < 400 copies/mL) by 39 weeks after ART initiation were investigated.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Of 254 children who initiated ART, 99 (39%) were cotreated for tuberculosis during follow-up. The mortality rate was 14%. Factors predicting mortality were lower pre-ART weight-for-age æ score and higher HIV RNA load. By 39 weeks, 84% of surviving children achieved viral suppression. Children who were not cotreated for tuberculosis were more likely to achieve viral suppression (94.8%) than were children who were receiving cotreatment at ART initiation (74.2%) or who started tuberculosis cotreatment after ART initiation (51.6%; P<.001). Other factors predicting lower probability of viral suppression were lower pre-ART weight-and length-forage æ score, higher HIV RNA load, and World Health Organization disease stage.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. High rates of viral suppression can be achieved among infants and young children who initiate protease-inhibitor-based ART. Cotreatment for tuberculosis reduced viral suppression. How best to treat HIV-infected children who require tuberculosis treatment warrants urgent investigation.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599269</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. The smallpox vaccine is associated with more serious adverse events than any other live attenuated vaccine in use today. Although studies have examined serum cytokine levels in primary vaccine recipients at 1 and 3-5 weeks after vaccination with the smallpox vaccine, serial measurements have not been performed, and studies in revaccinated subjects have not been conducted.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. The smallpox vaccine is associated with more serious adverse events than any other live attenuated vaccine in use today. Although studies have examined serum cytokine levels in primary vaccine recipients at 1 and 3-5 weeks after vaccination with the smallpox vaccine, serial measurements have not been performed, and studies in revaccinated subjects have not been conducted.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. We analyzed cytokine responses in both primary vaccine recipients and revaccinated subjects every other day for 2 weeks after vaccination.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Primary vaccine recipients had maximal levels of granulocyte-colony-stimulating factor on days 6-7 after vaccination; peak levels of tumor necrosis factor (TNF) ?, soluble TNF receptor 1, interferon (IFN)-?, IFN inducible protein-10 (IP-10), interleukin (IL)-6, and tissue inhibitor of metalloproteinases-1 on days 8-9 after vaccination; peak levels of soluble TNF receptor 2 and monokine induced by IFN-? (MIG) on days 10 11 after vaccination; and peak levels of granulocyte-macrophage-colony-stimulating factor on days 12-13 after vaccination. Primary vaccine recipients were significantly more likely to have higher peak levels of IFN-ã, IP-10, and MIG after vaccination than were revaccinated subjects. Primary vaccine recipients were significantly more likely to have fatigue, lymphadenopathy, and headache, as well as a longer duration of these symptoms and more hours missed from work, compared with revaccinated subjects.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. The increased frequency and duration of symptoms observed in primary vaccine recipients, compared with revaccinated subjects, paralleled the increases in serum cytokine levels in these individuals.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>5</TD><TD width='5%' bordercolor='blue'>Trial registration. Clinicaltrials. gov identifier NCT00325975.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599278</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Mucoviscosity-associated gene A (magA) is proposed to play a decisive role in the pathogenesis of liver abscesses due to Klebsiella pneumoniae. Although some investigators consider MagA to be a putative Oantigen ligase, it is also reportedly associated with the Kl antigen.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Mucoviscosity-associated gene A (magA) is proposed to play a decisive role in the pathogenesis of liver abscesses due to Klebsiella pneumoniae. Although some investigators consider MagA to be a putative Oantigen ligase, it is also reportedly associated with the Kl antigen.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Using magA-positive serotype Kl pneumoniae STL43 isolated from a patient with liver abscess, we constructed 3 bacterial mutants by targeting genes within the same transcription unit, including magA, wcaG, and rfbP. The virulence of these mutants was determined by neutrophil phagocytosis and inoculation of mice.Transmission electron microscopy and Western blot analysis were used to define their surface polysaccharides.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. STL43 was resistant, and all 3 mutants were highly susceptible, to phagocytosis. None of the mutant strains caused death in mice at the lethal dose of STL43. In contrast to previous reports, transmission electron microscopy revealed that all 3 mutants were nonencapsulated. Analysis of surface polysaccharides revealed that all 3 mutants retained their antigen but lost their antigen/capsule. Furthermore, amino acid analysis showed that MagA shared a conserved domain of Wzy, the serotype-specific capsular polysaccharide polymerase.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. In accordance with the bacterial polysaccharide gene nomenclature (BPGN) scheme, MagA should be renamed Wzy, the capsular polymerase specific to K. pneumoniae serotype Kl.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/40599276</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Nonsteroidal agonists have been developed that selectively bind to and activate estrogen receptor ? (ER?) rather than estrogen receptor ? (ER?). ER? is expressed equally in both male and female mammals in multiple extragonadal tissues. Work reported elsewhere has demonstrated that ER? agonists have beneficial effects in multiple (but not all) models of inflammatory diseases and also increase survival in experimentally induced sepsis.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Nonsteroidal agonists have been developed that selectively bind to and activate estrogen receptor ? (ER?) rather than estrogen receptor ? (ER?). ER? is expressed equally in both male and female mammals in multiple extragonadal tissues. Work reported elsewhere has demonstrated that ER? agonists have beneficial effects in multiple (but not all) models of inflammatory diseases and also increase survival in experimentally induced sepsis.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. In these experiments, ERß agonists (ERB-041 or WAY-202196) were compared with vehicle control in the murine cecal ligation and puncture (CLP) model and in the pneumococcal pneumonia model of sepsis.The effect of WAY-202196 on the gene expression profile in the CLP model was further studied by transcriptome analysis of lung and small intestine tissue samples.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. ER? agonists provided a significant survival benefit in both experimental models of bacterial sepsis.This survival advantage was accompanied by reduced histologie evidence of tissue damage, reduced transcription of multiple proinflammatory proteins by transcriptome analysis and was not associated with increased bacterial outgrowth.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. ER? agonist administration provided a survival advantage in septic animals and appears to be a promising therapeutic modality in sepsis.</TD></TR></table>
				
		</td>
		</tr>
	</table>		
</body>
</html>
